Sebastian Nijman Appointed Associate Member Of Ludwig Oxford

Ludwig Cancer Research announced today the appointment of Sebastian Nijman as Associate Member of its Oxford Branch. Nijman joins the Ludwig Institute for Cancer Research Oxford after several years as a principal investigator at the prestigious Research Center for Molecular Medicine of the Austrian Academy of Sciences, where he has developed cutting-edge technologies to explore the molecular interactions by which drugs - and drug candidates - exert their effects within cells. His aim is to apply such novel pharmacogenomic technologies to improve the use of existing cancer drugs and to develop novel therapies, with a special emphasis on breast and lung cancers.